Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells

April 19, 2022 | Comments Off on Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells

Frontiers in Cell and Development Biology 2022 March 22 [Link] Luca Hegedüs, Kata D Szücs, Matthias Kudla, Julian Heidenreich, Verena Jendrossek, Samuel Peña-Llopis, Tamas Garay, Andras Czirok, Clemens Aigner, Till…

Sulfated Glycans Recognized by S1 Monoclonal Antibody can Serve as a Diagnostic Marker for Malignant Pleural Mesothelioma

April 18, 2022 | Comments Off on Sulfated Glycans Recognized by S1 Monoclonal Antibody can Serve as a Diagnostic Marker for Malignant Pleural Mesothelioma

Lung 2022 April 8 [Link] Koki Nakashima, Yasuhiro Sakai, Hitomi Hoshino, Yukihiro Umeda, Hiroto Kawashima, Yoshitaka Sekido, Tamotsu Ishizuka, Motohiro Kobayashi Abstract Purpose: Malignant pleural mesothelioma (MPM) is a malignant…

Evaluation of DNA/RNA quality from cell block of malignant mesothelioma and lung adenocarcinoma

April 15, 2022 | Comments Off on Evaluation of DNA/RNA quality from cell block of malignant mesothelioma and lung adenocarcinoma

Diagnostic Cytopathology 2022 April 5 [Link] Shigenobu Tatsumi, Mao Takeuchi, Tomomi Fujii, Aya Sugimoto, Yoko Sekita-Hatakeyama, Takeshi Nishikawa, Tomoko Uchiyama, Kohei Morita, Hiroe Itami, Maiko Takeda, Masaharu Yamazaki, Chiho Ohbayashi…

Pulmonary Asbestos Fiber Burden is Related to Patient Survival in Malignant Pleural Mesothelioma

April 14, 2022 | Comments Off on Pulmonary Asbestos Fiber Burden is Related to Patient Survival in Malignant Pleural Mesothelioma

Journal of Thoracic Oncology 2022 March 30 [Link] Sanna Laaksonen, Eeva Kettunen, Eva Sutinen, Ilkka Ilonen, Tapio Vehmas, Timo Törmäkangas, Jari Räsänen, Henrik Wolff, Marjukka Myllärniemi Abstract Introduction: Malignant pleural…

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743

April 13, 2022 | Comments Off on First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743

Lung Cancer 2022 March 21 [Link] Arnaud Scherpereel, Scott Antonia, Yolanda Bautista, Francesco Grossi, Dariusz Kowalski, Gérard Zalcman, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S…

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

April 12, 2022 | Comments Off on Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

The Lancet Oncology 2022 April [Link] Hedy L Kindler, Silvia Novello, Alessandra Bearz, Giovanni L Ceresoli, Joachim G J V Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross…

Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials

April 11, 2022 | Comments Off on Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials

European Journal of Cancer 2022 March 28 [Link] Giuseppe Luigi Banna, Alessio Signori, Alessandra Curioni-Fontecedro, Alessio Cortellini, Marta Ponzano, Emilio Francesco Giunta, Sara Elena Rebuzzi, Samuel Chan, Vittorio Gebbia, Ronwyn…

Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients

April 8, 2022 | Comments Off on Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients

Lung Cancer 2022 March 19 [Link] Ludovic Fournel, Thomas Charrier, Maxime Huriet, Amedeo Iaffaldano, Audrey Lupo, Diane Damotte, Jennifer Arrondeau, Marco Alifano Abstract Background: Prediction of prognosis is a key…

Force-feeding malignant mesothelioma stem-cell like with exosome-delivered miR-126 induces tumour cell killing

April 7, 2022 | Comments Off on Force-feeding malignant mesothelioma stem-cell like with exosome-delivered miR-126 induces tumour cell killing

Translational Oncology 2022 March 23 [Link] Federica Monaco, Laura De Conti, Simone Vodret, Nunzia Zanotta, Manola Comar, Sandra Manzotti, Corrado Rubini, Laura Graciotti, Gianluca Fulgenzi, Massimo Bovenzi, Marco Baralle, Marco…

Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients

April 6, 2022 | Comments Off on Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients

Lung Cancer 2022 March 19 [Link] Ludovic Fournel, Thomas Charrier, Maxime Huriet, Amedeo Iaffaldano, Audrey Lupo, Diane Damotte, Jennifer Arrondeau, Marco Alifano Abstract Background: Prediction of prognosis is a key…

Categories